Lancet Oncol 2023 May
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.
Related Questions
Would you offer a FOLFIRI based regimen or TDxd?
New answer by Medical Oncologist at NYU Long Island School of Medicine (March 15, 2025)
It is important to remember the clinical context of the modern HER2 trials:1. MOUNTAINEER (Strickler et al., PMID 37142372): Chemotherapy Refractory ("fluoropyrimidines, oxali...